0001140361-13-045530.txt : 20131210
0001140361-13-045530.hdr.sgml : 20131210
20131210190345
ACCESSION NUMBER: 0001140361-13-045530
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131209
FILED AS OF DATE: 20131210
DATE AS OF CHANGE: 20131210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Raptor Pharmaceutical Corp
CENTRAL INDEX KEY: 0001070698
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 860883978
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0831
BUSINESS ADDRESS:
STREET 1: 9 COMMERCIAL BLVD
STREET 2: SUITE 200
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 415-382-1390
MAIL ADDRESS:
STREET 1: 9 COMMERCIAL BLVD
STREET 2: SUITE 200
CITY: NOVATO
STATE: CA
ZIP: 94949
FORMER COMPANY:
FORMER CONFORMED NAME: Raptor Pharmaceutical Corp.
DATE OF NAME CHANGE: 20090929
FORMER COMPANY:
FORMER CONFORMED NAME: TorreyPines Therapeutics, Inc.
DATE OF NAME CHANGE: 20061003
FORMER COMPANY:
FORMER CONFORMED NAME: AXONYX INC
DATE OF NAME CHANGE: 19990303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SAMANT VIJAY B
CENTRAL INDEX KEY: 0001198238
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-25571
FILM NUMBER: 131269451
MAIL ADDRESS:
STREET 1: 9373 TOWNE CENTRE DRIVE SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121-3088
4
1
doc1.xml
FORM 4
X0306
4
2013-12-09
0
0001070698
Raptor Pharmaceutical Corp
RPTP
0001198238
SAMANT VIJAY B
C/O RAPTOR PHARMACEUTICAL CORP.
5 HAMILTON LANDING, SUITE 160
NOVATO
CA
94949
1
0
0
0
Common Stock
2013-12-09
4
M
0
5000
5.13
A
5000
D
Common Stock
2013-12-09
4
S
0
5000
13.8621
D
0
D
Stock options (right to buy)
5.13
2013-12-09
4
M
0
5000
0
D
2011-12-22
2021-09-21
Common Stock
5000
5000
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 9, 2013.
Fully vested and exercisable.
This transaction was executed in multiple trades at prices ranging from $13.70 to $14.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
/s/ Kim R. Tsuchimoto, Raptor Pharmaceutical Corp., Attorney-in-fact
2013-12-10